This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AXSM Gets Positive FDA Feedback for Alzheimer's Agitation Drug Filing
by Zacks Equity Research
Based on the FDA's feedback, Axsome plans to submit a supplemental NDA for AXS-05 in Alzheimer's disease agitation in third-quarter 2025.
Ensign Group Expands Healthcare Portfolio With Key Acquisitions
by Zacks Equity Research
ENSG acquires skilled nursing and senior living facilities across four states, expanding its U.S. footprint and bringing higher revenues for its Skilled Services segment.
Rocket Pharmaceuticals Q4 Loss Narrower Than Estimates, Pipeline in Focus
by Zacks Equity Research
RCKT incurs a narrower-than-expected fourth-quarter 2024 loss. The company provides updates on its pipeline candidates.
NTLA's Q4 Loss Narrower Than Estimates, Revenues Increase Y/Y
by Zacks Equity Research
Intellia reports better-than-expected fourth-quarter 2024 results. The company provides updates on its pipeline candidates.
Perrigo's Q4 Earnings Beat Estimates, Revenues Decline Y/Y
by Zacks Equity Research
PRGO reports mixed Q4 2024 results. The decline in the company's top line is due to the loss of sales stemming from exited businesses and product lines.
Pacira Q4 Earnings Top, Revenues Miss Despite Exparel Sales Growth
by Zacks Equity Research
PCRX reports mixed fourth-quarter 2024 results, wherein earnings beat estimates but revenues miss. Exparel sales witness year-over-year growth.
IOVA Q4 Earnings Beat, Stock Down on Looming Economic Uncertainty
by Zacks Equity Research
Iovance reports better-than-expected fourth-quarter results. The stock plunges on warnings of adverse macroeconomic factors harming its business.
PBYI Stock Rises as Q4 Earnings & Sales Outpace Estimates
by Zacks Equity Research
Puma Biotechnology beats on fourth-quarter 2024 earnings and sales. The company issues a fresh financial guidance for 2025.
Compared to Estimates, Pacira (PCRX) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Pacira (PCRX) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Pacira (PCRX) Tops Q4 Earnings Estimates
by Zacks Equity Research
Pacira (PCRX) delivered earnings and revenue surprises of 5.81% and 0.03%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
CORT's Q4 Earnings and Revenues Fall Short of Estimates
by Zacks Equity Research
Corcept reports weaker-than-expected results for the fourth quarter of 2024. Korlym drives year-over-year sales.
MIRM's Q4 Loss Wider Than Expected, Revenues Beat Estimates
by Zacks Equity Research
Mirum's fourth-quarter 2024 earnings miss estimates while revenues beat the same.
Theravance's Q4 Loss In Line With Estimates, Sales Beat
by Zacks Equity Research
TBPH's fourth-quarter earnings match estimates while sales beat the same marginally. Increased collaboration revenues from Viatris drive revenues higher.
Sarepta Therapeutics (SRPT) Lags Q4 Earnings Estimates
by Zacks Equity Research
Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of -19.79% and 2.83%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
United Therapeutics Stock Down Despite Q4 Earnings & Sales Beat
by Zacks Equity Research
UTHR beats fourth-quarter estimates for both earnings and sales. Tyvaso sales fall short of estimates. Stock down in pre-market trading.
Beam Therapeutics' Q4 Earnings & Revenues Beat Estimates
by Zacks Equity Research
BEAM incurs a narrower-than-expected loss in the fourth quarter. The company remains focused on pipeline development.
Jazz Stock Gains as Q4 Earnings & Sales Surpass Expectations
by Zacks Equity Research
Jazz reports better-than-expected fourth-quarter results. Its newly issued EPS guidance of $22.50-$24.00 for full-year 2025 surpasses our expectations.
SANA Gears Up to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Sana Biotechnology's Q4 2024 earnings call, investors can expect updates regarding the developmental programs for its clinical-stage candidates.
SLGL Gears Up to Report Q4 Earnings: Here's What You Should Know
by Zacks Equity Research
Sol-Gel's fourth-quarter 2024 earnings are likely to have gained from higher licensing revenues from its partners.
Seeking Clues to Pacira (PCRX) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Pacira (PCRX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024.
Globalstar Gears Up for Q4 Earnings: Here's What You Should Know
by Zacks Equity Research
GSAT's Q4 2024 performance is likely to have been driven by continued momentum across Service and Subscriber equipment revenue segments.
CSTL Gears Up to Report Q4 Earnings: Here's What You Should Know
by Zacks Equity Research
Castle Biosciences' fourth-quarter 2024 earnings are likely to have gained from higher test volume growth of its dermatologic and non-dermatologic tests.
Intrusion Gears Up to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
INTZ's Q4 2024 performance is likely to have gained from higher Intrusion Shield sales and penetration in the government sector amid rising R&D costs.
What's in the Cards for Viatris Stock This Q4 Earnings?
by Zacks Equity Research
VTRS' Q4 results are likely to gain from new product launches in all major geographies.
SpringWorks' Q4 Loss Wider Than Expected, Revenues Beat Estimates
by Zacks Equity Research
SWTX reports mixed fourth-quarter 2024 results. Its newly approved desmoid tumor drug, Ogsiveo, witnesses a strong launch.